A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

ClinicalTrials.gov ID: NCT06994676

Public ClinicalTrials.gov record NCT06994676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Study identification

NCT ID: NCT06994676
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Crossbow Therapeutics, Inc.; Industry
Enrollment: 72 participants

Conditions and interventions

Conditions

Interventions

CBX-250 Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 15, 2025
Primary completion: Dec 31, 2026
Completion: May 31, 2027
Last update posted: Mar 15, 2026

2025 – 2027

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
Stanford Medical Center	Palo Alto	California	94304	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Northwestern Medicine	Chicago	Illinois	60611	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Washington University in St. Louis	St Louis	Missouri	63110	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Thomas Jefferson University Hospital	Philadelphia	Pennsylvania	19107	Recruiting
Sarah Cannon Cancer Institute	Nashville	Tennessee	37203	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06994676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 15, 2026 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06994676 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →